nSMOL for fast and precise mAb Bioanalysis

Article

Sponsored Content

Shimadzu’s new nSMOL Antibody BA reagent kit offers a unique and standardized workflow for the quantitation of monoclonal antibody drugs by LC-MS/MS in blood or other biological samples. The technique, called nano-Surface and Molecular-Orientation Limited (nSMOL) proteolysis, has been designed to minimize sample complexity while maintaining the specificity of the protein substrate for LC–MS/MS quantitation in therapeutic drug monitoring of mAbs. nSMOL proteolysis is an entirely novel solid-solid proteolysis method engineered to deliver highly efficient and quantitative detection of CDR peptides while decreasing the peptide numbers of the analytical target without antibody denaturation.

 

For more information on Shimadzu’s total solution for biopharmaceutical lab please visit:
www.shimadzu.eu/nsmol-antibody-ba-kit and https://www.youtube.com/watch?v=KoOarzAQg68

 

Recent Videos
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Pushing Tech Boundaries

Mike Hennessy Jr.
March 3rd 2025
Article

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

Rare Disease Day Celebrated on February 28

Patrick Lavery
March 1st 2025
Article

More than 6000 rare diseases—those which affect fewer than one in 2000 people each—are acknowledged in the medical community, with 72% of them being genetic.

Drug Solutions Podcast: Realizing AI’s Potential

Drug Solutions Podcast: Realizing AI’s Potential

Felicity Thomas
December 20th 2024
Podcast

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EMA Recommends Four Medicines for Approval in February

Susan Haigney
February 28th 2025
Article

Treatments for autoimmune diseases, multiple cancers, and skin blistering have been recommended for marketing approval.

Site Logo

Executive Summary: Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Inhaled Product Design and Development

Vectura Group plc;Vectura
February 28th 2025
Article

The regulatory landscape for bioequivalence continues to evolve, leveraging a broader suite of characterization techniques. These not only provide deeper product understanding, but also utility for generic product development as the potential for replacement of costly clinical studies becomes more of a reality.